...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug Design, Development and Therapy >Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors
【24h】

Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors

机译：盐酸戊乙奎醚：通过减弱Toll样受体治疗COPD的潜在药物

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The aim of this review was to evaluate and summarize the available scientific information on penehyclidine hydrochloride (PHC) for the treatment of chronic obstructive pulmonary disease (COPD) as a result of its ability to attenuate Toll-like receptors. Penehyclidine hydrochloride is an anticholinergic drug manufactured in China, with both antimuscarinic and antinicotinic activity. PHC is used widely in the clinic as a reversal agent in cases of organic phosphorus poisoning and soman poisoning, but also may also have an important role as a bronchodilator in the treatment of obstructive airway disease, including asthma and, in particular, COPD.Methods: Our bibliographic sources included the CAPLUS, MEDLINE, REGISTRY, CASREACT, CHEMLIST, CHEMCATS, and CNKI databases, updated to September 2012. In order to assess the data in detail, we used the search terms “penehyclidine hydrochloride,” “COPD,” “muscarinic receptor,” and “toll-like receptors.” Papers were restricted to those published in the English and Chinese languages, and to “paper” and “review” as the document type. Patents were also reviewed.Results: Our survey mainly yielded the results of research on PHC and the mechanisms of COPD. COPD is a preventable and treatable disease with some significant extrapulmonary manifestations that may contribute to its severity in some patients. Recently, it has been shown that muscarinic receptors may interact with Toll-like receptors. Basic and clinical studies of the relationship between the mechanism of action and the effects of PHC in the respiratory tract have been studied by a number of laboratories and institutions. The main advantages of PHC are that it has few M2 receptor-associated cardiovascular side effects and attenuates Toll-like receptors.Conclusion: PHC may be a promising candidate agent in the treatment of COPD in the future because of its ability to attenuate Toll-like receptors. This review should be of help to those intending to research this topic further.
机译：背景：这项审查的目的是评估和总结有关盐酸戊乙奎定（PHC）的有效科学信息，用于治疗慢性阻塞性肺疾病（COPD），因为它具有减弱Toll样受体的能力。盐酸戊乙奎定是一种在中国生产的抗胆碱能药物，具有抗毒蕈碱和抗烟碱活性。 PHC在临床上广泛用作有机磷中毒和梭曼中毒的逆转剂，但在支气管扩张剂（包括哮喘，尤其是COPD）的治疗中，PHC可能还起着重要的支气管扩张剂的作用。 ：我们的书目来源包括CAPLUS，MEDLINE，REGISTRY，CASREACT，CHEMLIST，CHEMCATS和CNKI数据库，这些数据库已更新至2012年9月。为了详细评估数据，我们使用了搜索词“盐酸戊乙奎醚”，“ COPD” “毒蕈碱受体”和“收费类受体”。论文仅限于以英文和中文发表的论文，并且以“论文”和“审阅”作为文档类型。结果：我们的调查主要产生了对PHC和COPD机制的研究结果。 COPD是一种可预防和治疗的疾病，具有一些重要的肺外表现，可能在某些患者中加剧其严重程度。最近，已经显示毒蕈碱受体可以与Toll样受体相互作用。许多实验室和机构已经研究了作用机理与PHC在呼吸道中的作用之间的关系的基础和临床研究。 PHC的主要优点是它几乎没有M2受体相关的心血管副作用，并能减弱​​Toll样受体。结论：由于PHC能够减弱Toll样，其在将来可能成为治疗COPD的有希望的候选药物。受体。这篇综述对打算进一步研究该主题的人应该有所帮助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号